Ru(II) complex mediated PDT for bladder cancer, Biology and dosimetry

Kaspler, Pavel; Lazic, Savo; Forward, Sarah; Arenas, Yaxal; Mandel, Arkady; Lilge, Lothar

doi:10.1109/lo.2016.7550018

Cited by 2 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There has been ongoing interest by a number of research groups in the use of the protein transferrin (Tf) to carry metal-based drugs as cargo to Tfreceptors that tend to be overexpressed on cancer cell surfaces. [152][153][154][155][156][157][158] Ru(II) transition metal complexes, including photosensitizers, have been shown to exhibit nonselective binding to both holo-and apo-Tf. This is also the case for TLD1433 and its derivatives, where Tfbinding both enhances and red-shifts the molar extinction coefficients of some of these photosensitizers under certain conditions.…”

Section: Future Directionmentioning

confidence: 99%

“…TLT has demonstrated that the photophysical properties of TLD1433 are improved by premixing TLD1433 and Tf, which includes reduced photobleaching, and that overall PDT efficacies are improved with a significant decrease in toxicity. 154 The TLD1433-Tf conjugate was named Rutherrin ® , with a Canadian patent pending, and is currently under clinical development for glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC). Rutherrin ® is able to cross the blood brain barrier (BBB) when sys-temically delivered to rats, with higher uptake by GBM cells relative to normal brain tissue.…”

Section: Future Directionmentioning

confidence: 99%

See 1 more Smart Citation

Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433

et al. 2018

View full text Add to dashboard Cite

Transition metal complexes are of increasing interest as photosensitizers in photodynamic therapy (PDT) and, more recently, for photochemotherapy (PCT). In recent years, Ru (II) polypyridyl complexes have emerged as the most widely studied systems for both PDT and PCT. Their rich photochemical and photophysical properties derive from a variety of excited-state electronic configurations accessible with visible and near-infrared light, and these properties can be exploited for both energy-and electron-transfer processes that can yield highly potent oxygen-dependent and/or oxygen-independent photobiological activity. Selected examples highlight the use of rational design in coordination chemistry to control the lowest-energy triplet excited state configurations for eliciting a particular type of photoreactivity for PDT and/or PCT effects. These principles are also discussed in the context of the development of TLD1433, the first Ru(II)-based photosensitizer for PDT to enter a human clinical trial. The design of TLD1433 arose from a tumor-centered approach, as part of a complete PDT package that included the light component and the protocol for treating nonmuscle invasive bladder cancer. Briefly, this review summarizes *

show abstract

Section: Future Directionmentioning

confidence: 99%

Section: Future Directionmentioning

confidence: 99%

Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433

et al. 2018

View full text Add to dashboard Cite

show abstract

“…During the active targeting of a tumor, a specific interaction of a molecule, such as a signaling peptide, oligonucleotide, oligosaccharide, protein, receptor targeting moiety or an antibody, is used to transport the therapeutic molecule. [32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47] A large variety of transition metal complexes have been successfully coupled to peptides resulting in increased receptor selectivity. [48][49][50] As examples for Ru(II) polypyridine complexes, the conjugation to the peptide hormone somatostatin showed a 100-fold increased selectivity for somatostatin receptor-expressing cells relative to the free PS.…”

Section: Introductionmentioning

confidence: 99%

Polymeric Encapsulation of a Ruthenium Polypyridine Complex for Tumor Targeted 1- and 2-Photon Photodynamic Therapy

Karges¹,

Li²,

Zeng³

et al. 2020

Preprint

View full text Add to dashboard Cite

Photodynamic therapy is a medical technique, which is gaining increasing attention to treat various types of cancer. Among the investigated classes of photosensitizers, the use of Ru(II) polypyridine complexes is gaining momentum. However, the currently investigated compounds generally show poor cancer cell selectivity. As a consequence, high drug doses are needed, which can cause side effects. To overcome this limitation, there is a need for the development of a suitable drug delivery system to increase the amount of PS delivered to the tumor. Herein, we report on the encapsulation of a promising Ru(II) polypyridyl complex into polymeric nanoparticles with terminal biotin groups. Thanks to this design, the particles showed much higher selectivity for cancer cells in comparison to non-cancerous cells in a 2D monolayer and 3D multicellular tumor spheroid model. As a highlight, upon intravenous injection of an identical amount of the Ru(II) polypyridine complex, an improved accumulation inside an adenocarcinomic human alveolar basal epithelial tumor of a mouse by a factor of 8.7 compared to the Ru complex itself was determined. The nanoparticles were found to have a high phototoxic effect upon 1-photon (500 nm) or 2-photon (800 nm) excitation with an eradication of an adenocarcinomic human alveolar basal epithelial tumor inside a mouse. Overall, this work describes, to the best of our knowledge, the first <i>in vivo</i> study demonstrating the cancer cell selectivity of a very promising Ru(II)-based PDT photosensitizer encapsulated into polymeric nanoparticles with terminal biotin groups.

show abstract

Ru(II) complex mediated PDT for bladder cancer, Biology and dosimetry

Cited by 2 publications

References 4 publications

Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433

Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433

Polymeric Encapsulation of a Ruthenium Polypyridine Complex for Tumor Targeted 1- and 2-Photon Photodynamic Therapy

Contact Info

Product

Resources

About